BioCentury | Dec 21, 2017
Preclinical News

New pathway could overcome resistance to TKIs in cancer

In a paper published in Cancer Research , researchers at Dana-Farber Cancer Institute and colleagues discovered that the recently identified ufmylation pathway plays a role in resistance to tyrosine kinase inhibitors (TKIs), and suggested that promoting...
BioCentury | Mar 24, 2016
Distillery Therapeutics

Therapeutics: Drug-responsive transcription factor PDR1 (PDR1); mediator complex subunit 15 (MED15)

Infectious disease INDICATION: Fungal infection Cell culture, moth and mouse studies suggest inhibiting the microbial PDR1- MED15 interaction could help treat multidrug-resistant (MDR) fungal infections, which frequently involve gain-of-function mutations in PDR1 . Screening of a...
BioCentury | Mar 10, 2016
Targets & Mechanisms

Brown fat heats up

While FGF21 is the clear frontrunner target for stimulating brown and beige fat, players in the seven year-old field believe there's room for plenty more runners in the race. Since the start of the year,...
BioCentury | Apr 25, 2013
Cover Story

Super-enhancing discovery

Boston researchers have detailed a class of regulatory elements, dubbed super-enhancers, that control the expression of genes, including oncogenes, that are key to determining cellular identity. 1,2 The findings may explain how some compounds that...
BioCentury | Apr 25, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Using chromatin immunoprecipitation followed by whole-genome sequencing (ChIP-Seq) to identify disease-associated super-enhancer regulatory elements Cell culture studies suggest mapping super-enhancers could help identify drug targets...
BioCentury | Dec 6, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Transforming growth factor-b receptor II (TGFb-RII; TGFBR2); mediator complex subunit 12 (MED12) In vitro studies suggest inhibiting TGFBR2 could help...
BioCentury | May 3, 2012
Cover Story

Heart beats fat

Researchers from The University of Texas Southwestern Medical Center have discovered that knocking down microRNA-208a in the heart leads to systemic benefits in obesity and metabolic disease, in addition to the already known effects on...
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Endocrine disease

Endocrine disease Diabetes; obesity Mediator complex subunit 1 (MED1) Mouse studies suggest that inhibiting MED1 in skeletal muscle could help treat obesity or diabetes. Mice with skeletal muscle-specific Med1 knockout had greater insulin sensitivity and...
Items per page:
1 - 8 of 8